GSA Capital Partners LLP Sells 76,735 Shares of Kodiak Sciences Inc. $KOD

GSA Capital Partners LLP decreased its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 46.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 87,697 shares of the company’s stock after selling 76,735 shares during the quarter. GSA Capital Partners LLP owned 0.17% of Kodiak Sciences worth $1,436,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Headlands Technologies LLC grew its holdings in shares of Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after purchasing an additional 5,815 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in shares of Kodiak Sciences by 21.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company’s stock worth $56,000 after buying an additional 2,691 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Kodiak Sciences in the 1st quarter valued at $94,000. Jane Street Group LLC boosted its holdings in shares of Kodiak Sciences by 441.3% during the 1st quarter. Jane Street Group LLC now owns 64,649 shares of the company’s stock valued at $181,000 after acquiring an additional 52,705 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in Kodiak Sciences during the 1st quarter worth $188,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Kodiak Sciences news, Director Bros. Advisors Lp Baker acquired 2,608,696 shares of the stock in a transaction dated Thursday, December 18th. The stock was purchased at an average cost of $23.00 per share, with a total value of $60,000,008.00. Following the transaction, the director owned 18,358,772 shares in the company, valued at approximately $422,251,756. The trade was a 16.56% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 45.90% of the company’s stock.

Kodiak Sciences Stock Performance

Kodiak Sciences stock opened at $22.66 on Wednesday. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -5.50 and a beta of 2.64. Kodiak Sciences Inc. has a 52-week low of $1.92 and a 52-week high of $31.18. The firm has a 50 day moving average price of $25.78 and a two-hundred day moving average price of $18.69.

Analyst Ratings Changes

Several research firms have commented on KOD. Chardan Capital reiterated a “neutral” rating and issued a $14.00 target price on shares of Kodiak Sciences in a research report on Monday, November 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. UBS Group initiated coverage on shares of Kodiak Sciences in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price on the stock. JPMorgan Chase & Co. upgraded shares of Kodiak Sciences from a “neutral” rating to an “overweight” rating and upped their price target for the company from $15.00 to $24.00 in a research report on Friday, October 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $38.00 price target on shares of Kodiak Sciences in a report on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $28.29.

Kodiak Sciences Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.